[Chronochemotherapy]

Same author

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy.

ESMO open·2025

Same author

Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.

ESMO open·2025

Same author

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Same author

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.

Cell death & disease·2022

Same author

Prevalence and risk factors for gonococcal infection in Reunion Island.

Infectious diseases now·2021

Same author

Risk factors associated with severe perineal tears: A five-year study.

Journal of gynecology obstetrics and human reproduction·2020

Same journal

End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.

Tumori·2026

Same journal

Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.

Tumori·2026

Same journal

Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.

Tumori·2026

Same journal

Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.

Tumori·2026

Same journal

Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.

Tumori·2026

Same journal

Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.

Tumori·2026

Related Experiment Videos

[Chronochemotherapy]

Related Concept Videos

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy.

Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.

Prevalence and risk factors for gonococcal infection in Reunion Island.

Risk factors associated with severe perineal tears: A five-year study.

End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.

Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.

Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.

Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.

Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.

Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.

Related Experiment Videos

[Chronochemotherapy]

Related Concept Videos

Related Articles

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy.

Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.

Prevalence and risk factors for gonococcal infection in Reunion Island.

Risk factors associated with severe perineal tears: A five-year study.

End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.

Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.

Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.

Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.

Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.

Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.